Biomea Fusion, Inc.
For the period ended Jun 30, 2025. Filed Aug 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 5, 2025
BMEA$0.55-8.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
(in thousands, except share data)
| Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders' | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balance at December 31, 2024 | 36,310,713 | $4 | $438,820 | $(387,251) | $51,573 |
| Issuances of common stock under at the market equity offering program, net of issuance costs of $5 | 1,261,537 | — | 3,257 | — | 3,257 |
| Stock-based compensation expense | — | — | 3,169 | — | 3,169 |
| Net loss | — | — | — | (29,262) | (29,262) |
| Balance at March 31, 2025 | 37,572,250 | 4 | 445,246 | (416,513) | 28,737 |
| Purchases under employee stock purchase plan | 95,421 | — | 117 | — | 117 |
| Issuances of common stock under at the market equity offering program, net of issuance costs of $129 | 1,009,585 | — | 1,651 | — | 1,651 |
| Issuance of common stock and pre-funded warrants under the public offering, net of issuance costs of $2,815 | 19,450,000 | 2 | 15,170 | — | 15,172 |
| Stock-based compensation expense | — | — | 2,573 | — | 2,573 |
| Net loss | — | — | — | (20,740) | (20,740) |
| Balance at June 30, 2025 | 58,127,256 | $6 | $464,757 | $(437,253) | $27,510 |
| Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders' | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balance at December 31, 2023 | 35,866,610 | $4 | $418,058 | $(248,825) | $169,237 |
| Issuance of restricted stock | 44,226 | — | — | — | — |
| Exercise of stock options | 22,750 | — | 116 | — | 116 |
| Stock-based compensation expense | — | — | 5,022 | — | 5,022 |
| Net loss | — | — | — | (39,061) | (39,061) |
| Balance at March 31, 2024 | 35,933,586 | 4 | 423,196 | (287,886) | 135,314 |
| Issuance of restricted stock | 16,833 | — | — | — | — |
| Exercise of stock options | 72,795 | — | 333 | — | 333 |
| Purchases under employee stock purchase plan | 161,271 | — | 737 | — | 737 |
| Stock-based compensation expense | — | — | 4,840 | — | 4,840 |
| Net loss | — | — | — | (37,276) | (37,276) |
| Balance at June 30, 2024 | 36,184,485 | $4 | $429,106 | $(325,162) | $103,948 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.